Navigation Links
Provitro Biosciences Awarded First-Ever U.S. Patent For Large-Scale Production Of Bamboo Plants
Date:5/7/2013

MT. VERNON, Wash., May 7, 2013 /PRNewswire/ -- Provitro Biosciences LLC (or "Provitro"), a subsidiary of Pendrell Corporation (NASDAQ: PCO) today received a patent from the United States Patent and Trademark Office covering foundational technologies that enable the rapid, disease-free, and high volume production of bamboo plants for the first time.   The patent issued today reflects more than a decade of innovative research by Provitro in the field of non-genetically modified commercial-scale plant propagation methods.

Provitro was awarded U.S. Patent No. 8435789, "Media, Kits, Systems and Methods for the Micropropagation of Bamboo," which focuses on methods of propagating bamboo by including certain plant growth regulators in the medias used for initiating bamboo shoots from plant explants and then rapidly multiplying the number of shoots.  This key innovation is the result of years of intensive research and development that for the first time enables the production of numerous, healthy bamboo plants for large-scale field plantings, including for the ornamental and timber bamboo industries. 

"The technology developed by Provitro lays the foundation for serving vast global markets with a reliable, economical and environmentally beneficial source of alternative fiber that has previously not been available on a commercial scale," commented Jackie Heinricher , chief executive officer of Provitro Biosciences.  "This patent reflects years of groundbreaking research efforts by the Provitro team, and underscores the potential we see in this technology."  

In addition to this issued U.S. patent, Provitro Biosciences has a large, active intellectual property portfolio for the worldwide protection of its proprietary technologies.  The company anticipates that this is j
'/>"/>

SOURCE Pendrell Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Regado Biosciences, Inc. Files Registration Statement for Proposed Initial Public Offering
2. Quanta BioSciences qRT-PCR technology recommended in newly published CDC protocol for detection of H7N9 Avian Influenza
3. Centrillion Biosciences Announces Next-Gen Sequencing Innovation Grant Program
4. Sangamo BioSciences Announces Presentation At The Needham Healthcare Conference
5. Sangamo BioSciences Announces Presentation At Regen Med Investor Day
6. Further Advancements Made in the Development of an Improved Method For Rape Kit Testing Using Pressure BioSciences Patented Pressure Cycling Technology (PCT)
7. Northstar Biosciences Launches All Natural Skincare Solutions
8. New Applications of Pressure BioSciences PCT Platform Prominently Featured at Scientific Conference on Technologies for Protein Research
9. INVENT Ventures and Heliant Ventures Seek to Accelerate Personalized Medicine Research, Co-Invest in Sanguine BioSciences
10. INVENT Ventures and Heliant Ventures Seek to Accelerate Personalized Medicine Research with Seed Round Investment in Sanguine BioSciences
11. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Canada (PRWEB) January 15, 2014 This ... on nonclinical and clinical safety assessment in biosimilars. , ... path for biosimilar drug development, however the complex nature ... to quality, safety and efficacy extremely challenging. Based on ...
(Date:1/15/2014)... Two champions of science, technology, engineering, ... an annual competition for middle and high school students ... STEM study. The competition presents students with real-world problems ... Aptitude, Mathematics, and Sciences is a program administered ...
(Date:1/15/2014)... Arizona (PRWEB) January 15, 2014 2013 ... for Scottsdale’s Brain State Technologies®. They saw continued independent ... Medical Center who were awarded a $1 million grant ... published in “Brain and Behavior” a peer reviewed journal, ...
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that ... leading Russian pharmaceutical company, to develop and commercialize nemonoxacin ... , Turkey and other ... novel antibiotic for the treatment of bacterial infections including ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... Commercialization of the Revolutionary ... Accuri C6 Flow Cytometer(R) System--, ... a life,sciences company developing revolutionary bench-top flow cytometer systems,today ... financing led by,Fidelity Biosciences and Flagship Ventures. Current investors ...
... 8 Concentric Pharma Advertising, Inc., a,five-year-old ... growing in the,field, has been selected by ... a developmental once-daily,medication for the treatment of ... include a broad range of activities,including branding, ...
... 7 American Oriental,Bioengineering, Inc. (NYSE: AOB ... market conditions and other factors, $85 million aggregate,principal ... qualified,institutional buyers in a private placement exempt from ... as amended (the "Securities,Act")., AOB currently expects ...
Cached Biology Technology:Accuri Cytometers Completes $13 Million Series C Financing 2Accuri Cytometers Completes $13 Million Series C Financing 3Accuri Cytometers Completes $13 Million Series C Financing 4Concentric Wins Full-Service Professional Assignment From Biopharm Innovator Neuromed 2American Oriental Bioengineering Proposes Offering of $85 Million of Convertible Notes 2American Oriental Bioengineering Proposes Offering of $85 Million of Convertible Notes 3
(Date:4/23/2014)... The trope that the likelihood of an accurate group ... not hold up when a collective faces a variety ... nature. Instead, Princeton University researchers report that smaller groups ... assemblies may become excessively focused on only certain pieces ... to what is known about collective intelligence, or the ...
(Date:4/23/2014)... turning away from using triclosan as an antimicrobial ingredient ... And now scientists are reporting new evidence that appears ... ACS journal Chemical Research in Toxicology , found ... octylphenol, promoted the growth of human breast cancer cells ... , Kyung-Chul Choi and colleagues note that hormonal imbalances ...
(Date:4/23/2014)... disease is the first cause of dementia and affects ... cure has yet been found. One of the reasons ... cellular mechanisms which cause alterations in nerve transmissions and ... the disease., Researchers from the Institute of Neuroscience at ... mechanism involved in memory consolidation and were able to ...
Breaking Biology News(10 mins):Too many chefs: Smaller groups exhibit more accurate decision-making 2Too many chefs: Smaller groups exhibit more accurate decision-making 3In lab tests, the antimicrobial ingredient triclosan spurs growth of breast cancer cells 2Loss of memory in Alzheimer's mice models reversed through gene therapy 2
... This press release is available in French ... and men contribute equally to the lineage of contemporary populations? ... polygamy or monogamy? To answer these questions, Dr. Damian Labuda, ... a professor at the Department of Pediatrics of the Universit ...
... professor of chemistry at New Jersey Institute of ... patent today for a novel composition of matter. ... (US Patent Number 7,670,684) discloses a new self-contained ... comprised of organic scaffolds with metal centers, which ...
... worldwide. It is the most common form of age-related dementia, ... no cure, and the available drugs only help to relieve ... characteristic changes in the brains of Alzheimer,s patients is the ... curing or at least slowing the disease lies in developing ...
Cached Biology News:Modern man found to be generally monogamous, moderately polygamous 2NJIT researcher awarded patent for hydrophobic, corrosion-resistant coating 2The sea squirt offers hope for Alzheimer's sufferers 2
Monoclonal Anti-Gα o purified immunoglobulin buffered aqueous solution Solution in phosphate buffered saline pH 7.4, containing 0.08% sodium azide. partially purified bovine brain Gα O ...
Sheep polyclonal to ErbB 2 ( Abpromise for all tested applications). Antigen: Recombinant full length c-ErbB2 protein (Human). Entrez GeneID: 2064 Swiss Protein ID: P04626...
... cis- 9-Octadecenoyl-N-hydroxylamide Oleoyl-N-hydroxylamide White solid. ... A potent inhibitor of MMP-2 that acts ... = 1.7 μM). Purity: ≥98% by ... Unstable in solution, reconstitute just prior to ...
MAb to Vasopressin Preservative: NaN3...
Biology Products: